Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Safety concerns hang over new Alzheimer's treatment

Two deaths linked to the drug may present a more complicated path to approval.

Axsome Hits The Stratosphere On Alzheimer's News As Biogen Faces A Setback

Axsome Hits The Stratosphere On Alzheimer's News As Biogen Faces A Setback

Axsome Therapeutics said its Alzheimer's treatment met the goals of a study, sending its shares into the stratosphere, while Biogen's Alzheimer's effort had a setback.

Investors Business Daily

Gene therapy at $3.5m a dose approved for US adults with hemophilia B

Gene therapy at $3.5m a dose approved for US adults with hemophilia B

Hemgenix frees patients from repeated treatments but initial cost makes it most expensive medicine in the world

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

‘This looks like the real deal’: are we inching closer to a treatment for Alzheimer’s?

After years of setbacks, dementia researchers are getting excited about a new antibody drug called lecanemab. No one expects it to stop cognitive decline, but even slowing it would be a breakthrough

The Guardian - UK

2 Stocks You Could Keep in Your Portfolio Forever

Despite signs of inflation cooling in the United States, the IMF is not expecting the global economic picture to improve anytime soon. However, the cooling inflation might induce the Fed to ease the pace of rate hikes. As economic uncertainties remain, we think fundamentally solid stocks McDonald’s (MCD) and Biogen…

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm

The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.

Investors Business Daily

Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others

Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Patience At The Right Time Made LLY Stock A Swing Trading Winner

Patience At The Right Time Made LLY Stock A Swing Trading Winner

Patience is a virtue but knowing the right time to apply it helps make you money.

Investors Business Daily

Biogen tabs veteran pharma leader Viehbacher as next CEO

Biogen tabs veteran pharma leader Viehbacher as next CEO

Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm

The Independent UK

Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles

Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles

Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements.

Investors Business Daily

10 Stocks Turned $10,000 To $197,394 In 10 Months

10 Stocks Turned $10,000 To $197,394 In 10 Months

Investors finally got a decent month in the S&P 500. And some really maximized their gains.

Investors Business Daily

Stock Market Rally Resilient As Apple Bucks Megacap Meltdown: Weekly Review

Stock Market Rally Resilient As Apple Bucks Megacap Meltdown: Weekly Review

The market rally was volatile but ultimately rallied broadly. Amazon, Meta, Google and Microsoft sold off on earnings, as Apple jumped on results.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022

Nasdaq And Small Caps Power Stock Market Gains; Medpace, GM And Coke Earnings Pace Stocks

Nasdaq And Small Caps Power Stock Market Gains; Medpace, GM And Coke Earnings Pace Stocks

Stock market gains despite slide in consumer confidence General Motors, Coca-Cola, Medpace and others posted earnings bumps.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biogen Skids Despite Beat-And-Raise Quarter As Pressure Builds In Alzheimer's Market

Biogen stock fell Tuesday despite a beat-and-raise quarter and continued enthusiasm for its experimental Alzheimer's treatment.

Biogen Whale Trades For October 20

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades.

Tribune News Service

For Alzheimer’s patients, a controversial drug brings hope

TAMPA, Fla. -- At 53, Michele Hall was at the height of her legal career. She’d just sent her three kids to college. She had decades ahead with her husband Doug — after nearly 30 years of marriage, the couple looked forward to celebrating 30 more.

This Is What Whales Are Betting On Biogen

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity

Biogen could easily take on Roche and Eli Lilly in Alzheimer's treatment, an analyst said Thursday as he upgraded Biogen stock.

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022

2 Stocks with Great Track Records to Buy Right Now

Despite the Fed's aggressive interest rate hikes, the job market remains strong. However, given the mounting recessionary fears, it may be prudent to invest in UnitedHealth Group (UNH) and Biogen (BIIB), based on their solid fundamentals and impressive growth prospects. Continue Reading….

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022

The Conversation

New Alzheimer's drug slows cognitive decline – and may be available as early as next year

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

Tribune News Service

Mayo Clinic expert offers perspective on experimental Alzheimer's disease drug

According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer's disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical decline of people with Alzheimer's disease by 27% compared with a placebo after 18 months of treatment.

‘Historic moment’: Drug slows cognitive decline in Alzheimer’s

It's being widely reported that an experimental drug has slowed the cognitive decline and brain damage in Alzheimer's patients.

People

Kritika SarmahHer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Alzheimer Disease

Places

265,071 stories

110,369 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play